Literature DB >> 19451852

Ventilator-associated pneumonia in pediatric trauma patients.

Breena R Taira1, Kimberly E Fenton, Thomas K Lee, Hongdao Meng, Jane E McCormack, Emily Huang, Adam J Singer, Richard J Scriven, Marc J Shapiro.   

Abstract

BACKGROUND: Ventilator-associated pneumonia (VAP) is a significant cause of secondary morbidity and mortality in adult trauma patients. No study has characterized VAP in pediatric trauma patients. We determined the rates of and potential risk factors for VAP in pediatric trauma patients.
METHODS: A countywide trauma registry identified all pediatric trauma patients with potential VAP treated at a Regional Trauma Center. After a structured chart review, descriptive statistics were used to characterize the population.
RESULTS: One hundred fifty-eight trauma patients younger than 16 years requiring intubation and mechanical ventilation were identified in 3388 pediatric trauma admissions from the period 1995-2006. Drownings and poisonings were excluded. The registry identified 14 potential VAPs, of which, on detailed review, 7 were true cases. The VAP rate for pediatric trauma patients was 0.2% overall or 4.4% of those mechanically ventilated. In addition, ventilator days were available in the registry from 2003 forward and the rate in ventilator days was found to be 13.83/1000. Although higher than the overall pediatric intensive care unit VAP rate (5.93/1000 ventilator days), the pediatric trauma VAP rate was substantially lower than the VAP rate in adult trauma patients (58.25/1000 ventilator days). On chart review, six of the seven patients were male and older than 10 years (mean age, 11.9 years). All seven patients with VAP were blunt trauma victims with head injury (mean initial Glasgow Coma Score, 5.6) with Injury Severity Scores over 25 (mean, 32.1). Pulmonary contusion was present in four of the seven. Although the in-hospital mortality rate of ventilated pediatric trauma patients was 17.1%, there was no mortality in those with VAP.
CONCLUSIONS: The rate of VAP in pediatric trauma patients is substantially lower than in similar adults. Age older than 10 years, blunt trauma, head injury, and Injury Severity Score >25 may be risk factors. VAP is not associated with increased mortality in pediatric trauma patients.

Entities:  

Mesh:

Year:  2009        PMID: 19451852     DOI: 10.1097/PCC.0b013e3181a3108d

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  8 in total

1.  Risk factors and outcome of Ventilator Associated Tracheitis (VAT) in pediatric trauma patients.

Authors:  Maroun J Mhanna; Ibrahim S Elsheikh; Dennis M Super
Journal:  Pediatr Pulmonol       Date:  2012-04-24

2.  Strain differences in alveolar neutrophil infiltration and macrophage phenotypes in an acute lung inflammation model.

Authors:  Yinzhong Zhang; Xinchun Lin; Kiyokazu Koga; Koichiro Takahashi; Helena M Linge; Adriana Mello; Teresina Laragione; Percio S Gulko; Edmund J Miller
Journal:  Mol Med       Date:  2011-04-28       Impact factor: 6.354

3.  Ventilator-Associated Pneumonia in Pediatric Traumatic Brain Injury.

Authors:  Mitchell Hamele; Chris Stockmann; Meghan Cirulis; Jay Riva-Cambrin; Ryan Metzger; Tellen D Bennett; Susan L Bratton
Journal:  J Neurotrauma       Date:  2015-10-02       Impact factor: 5.269

4.  Comparison of the New Adult Ventilator-Associated Event Criteria to the Centers for Disease Control and Prevention Pediatric Ventilator-Associated Pneumonia Definition (PNU2) in a Population of Pediatric Traumatic Brain Injury Patients.

Authors:  Meghan M Cirulis; Mitchell T Hamele; Chris R Stockmann; Tellen D Bennett; Susan L Bratton
Journal:  Pediatr Crit Care Med       Date:  2016-02       Impact factor: 3.624

5.  Economic analysis of a pediatric ventilator-associated pneumonia prevention initiative in nicaragua.

Authors:  Edward I Broughton; Sergio R López; María Nela Aguilar; María Mercedes Somarriba; Magaly Pérez; Nieves Sánchez
Journal:  Int J Pediatr       Date:  2012-02-08

6.  Inherent Risk Factors for Nosocomial Infection in the Long Stay Critically Ill Child Without Known Baseline Immunocompromise: A Post Hoc Analysis of the CRISIS Trial.

Authors:  Joseph A Carcillo; J Michael Dean; Richard Holubkov; John Berger; Kathleen L Meert; Kanwaljeet J S Anand; Jerry Zimmerman; Christopher J Newth; Rick Harrison; Jeri Burr; Douglas F Willson; Carol Nicholson; Michael J Bell; Robert A Berg; Thomas P Shanley; Sabrina M Heidemann; Heidi Dalton; Tammara L Jenkins; Allan Doctor; Angie Webster
Journal:  Pediatr Infect Dis J       Date:  2016-11       Impact factor: 2.129

7.  Interaction Between 2 Nutraceutical Treatments and Host Immune Status in the Pediatric Critical Illness Stress-Induced Immune Suppression Comparative Effectiveness Trial.

Authors:  Joseph A Carcillo; J Michael Dean; Richard Holubkov; John Berger; Kathleen L Meert; Kanwaljeet J S Anand; Jerry J Zimmerman; Christopher J L Newth; Rick Harrison; Jeri Burr; Douglas F Willson; Carol Nicholson; Michael J Bell; Robert A Berg; Thomas P Shanley; Sabrina M Heidemann; Heidi Dalton; Tammara L Jenkins; Allan Doctor; Angie Webster; Robert F Tamburro
Journal:  JPEN J Parenter Enteral Nutr       Date:  2016-09-22       Impact factor: 4.016

8.  Incidences and influences of device-associated healthcare-associated infections in a pediatric intensive care unit in Japan: a retrospective surveillance study.

Authors:  Takeshi Hatachi; Kazuya Tachibana; Muneyuki Takeuchi
Journal:  J Intensive Care       Date:  2015-10-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.